Willow Biosciences Inc.
Willow Biosciences are pioneers in the biotechnology sector and have developed the only fully-integrated synthetic biology solution for opioid biosynthesis. We are now leveraging our unique design-build process to the biosynthesis of cannabinoids.
Willow Biosciences Inc. (WLLW)
Le 17 mai/May 2019
Willow Biosciences Inc. has announced a consolidation of its issued and outstanding share capital on the on the basis of one (1) post-consolidation Common Share for each twenty-five (25) pre-consolidation Common Shares (the "Consolidation")
As a result, the outstanding shares of the company will be reduced to approximately 69,350,763.
The shares will begin trading on a consolidated basis and with a new CUSIP number on May 21, 2019.
The name and symbol will not change.